Prima BioMed Ltd (PRR.AX) (PBMD) is a globally active and listed (ASX, NASDAQ) biotechnology company focused on developing novel oncology therapies in the field of immunotherapy. Prima BioMed has a clear strategy to develop and commercialize therapeutic vaccine CVac™ in ovarian cancer with an opportunity to expand to other indications. CVac™ has been tested successfully in two clinical studies and is currently in late stage clinical development in Australia, USA and Europe. Long term goal of Prima BioMed is the development of commercial cancer therapies on a worldwide scale.
The company has advised that it will hold a shareholder briefing with the Company's CEO designate Matthew Lehman, current CEO Martin Rogers, Chairman Lucy Turnbull, and Deputy Chairman Albert Wong in Sydney, Australia, on Friday, 15 June 2012.
The briefing will provide an opportunity for Mr. Lehman to meet shareholders and deliver an update on the Company's activities.
Mr. Lehman, who is currently Prima's Chief Operating Officer, will become the Company's CEO effective 1 September 2012 (see ASX announcement of 24 May).
Details of the shareholder briefing:
Date:
Friday, 15 June 2012
Time:
9:30am to 11:00am AEST (local time)
Venue:
Radisson Blu Hotel Sydney
27 O'Connell St Sydney (Marble Room 2 and 3)
Shareholders outside Sydney will be able to access the briefing via a webcast and dial-in facility. Webcast and dial-in details will be provided on the Prima BioMed and ASX websites prior to the meeting.
Shareholders, and other interested parties, are kindly requested to RSVP to enquiries@primabiomed.com.au prior to the event to assist in planning the meeting. Shareholders are also encouraged to submit questions or comments via email prior to the meeting.
Prima has updated the Company Calendar section of its website to include this shareholder briefing and other relevant upcoming public presentations.